Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $43.00 Price Target at The Goldman Sachs Group

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price target dropped by The Goldman Sachs Group from $48.00 to $43.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would indicate a potential upside of 260.74% from the company’s current price.

A number of other research analysts have also recently commented on DAWN. Bank of America cut their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. Finally, TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Trading Up 0.4 %

Shares of DAWN opened at $11.92 on Monday. Day One Biopharmaceuticals has a twelve month low of $11.13 and a twelve month high of $18.07. The company has a market cap of $1.20 billion, a P/E ratio of -11.57 and a beta of -1.46. The company’s fifty day simple moving average is $12.55 and its 200-day simple moving average is $13.58.

Insiders Place Their Bets

In other news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the sale, the insider now owns 1,034,015 shares of the company’s stock, valued at $13,762,739.65. This trade represents a 2.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB boosted its stake in Day One Biopharmaceuticals by 16.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock worth $376,000 after purchasing an additional 3,900 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after buying an additional 1,002 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 87.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,203 shares of the company’s stock valued at $267,000 after buying an additional 8,935 shares during the period. SteelPeak Wealth LLC grew its position in Day One Biopharmaceuticals by 9.8% in the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after acquiring an additional 1,550 shares in the last quarter. Finally, TimesSquare Capital Management LLC lifted its position in shares of Day One Biopharmaceuticals by 8.2% during the third quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock worth $25,460,000 after purchasing an additional 139,160 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.